Vericel VCEL Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Product sales, net by Product | |||||
| Biopsy kits | $2.61M+24.6% | $2.09M+0.1% | $2.09M0.0% | $2.09M-4.7% | |
| Epicel | $32.07M-12.4% | $36.62M+16.0% | $31.57M-0.5% | $31.73M-23.6% | |
| M A C I Implants and kits | $239.51M+21.4% | $197.31M+19.7% | $164.8M+24.9% | $131.97M+18.3% | |
| MACI implants, kits, and instruments | $179.5M+27.2% | $141.1M+33.9% | $105.4M+30.2% | $80.95M+12.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vericel break its business down?
- Vericel (VCEL) reports product sales, net by product across 4 parts — Biopsy kits, Epicel, M A C I Implants and kits and MACI implants, kits, and instruments. Each is extracted from the segment footnotes and tracked over time.
- Where does Vericel's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vericel's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.